Increase/Decrease in Cash: The total change in cash for the company over the given period.
Sangamo Therapeutics, Inc. (SGMO) had Increase/Decrease in Cash of $6.64M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$1.44M |
|
$-31.00M |
|
-- |
|
$1.44M |
|
$33.39M |
|
$-31.95M |
|
$0.95M |
|
$-31.00M |
|
$-31.00M |
|
$-31.00M |
|
$-31.00M |
|
$-31.00M |
|
$-31.00M |
|
$-31.95M |
|
$-31.07M |
|
389.62M |
|
389.62M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$37.11M |
|
$10.32M |
|
$22.85M |
|
$59.97M |
|
$53.13M |
|
-- |
|
$25.79M |
|
$78.92M |
|
$-18.95M |
|
$-18.95M |
|
$-18.95M |
|
414.27M |
|
| Cash Flow Statement Financials | |
$-19.28M |
|
$-0.01M |
|
$26.70M |
|
$20.95M |
|
$27.59M |
|
|
Increase/Decrease in Cash |
$6.64M |
$0.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2215.39% |
|
-2215.39% |
|
-- |
|
-2149.45% |
|
-2149.45% |
|
$-19.30M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
1.65 |
|
54.49 |
|
163.52% |
|
163.52% |
|
-51.69% |
|
163.52% |
|
$-0.05 |
|
$-0.05 |
|
$-0.05 |
|